900513-88-4

Basic information

• Product Name: 2-(3-Benzyloxy-pyrrolidin-1-yl)-cyclohexanol
• Synonyms: 2-(3-Benzyloxy-pyrrolidin-1-yl)-cyclohexanol;(1R,2R)-2-((R)-3-(benzyloxy)pyrrolidin-1-yl)cyclohexanol
• CAS NO: 900513-88-4
• Molecular Formula: C₁₇H₂₅NO₂
• Molecular Weight: 275.3859
• EINECS: -0
• Mol File: 900513-88-4.mol

Chemical Properties

• Boiling Point: 400.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• PKA: 14.95±0.40(Predicted)
• CAS DataBase Reference: 2-(3-Benzyloxy-pyrrolidin-1-yl)-cyclohexanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-Benzyloxy-pyrrolidin-1-yl)-cyclohexanol(900513-88-4)
• EPA Substance Registry System: 2-(3-Benzyloxy-pyrrolidin-1-yl)-cyclohexanol(900513-88-4)

Safety Data

• Hazardous Substances Data: 900513-88-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(3-Benzyloxy-pyrrolidin-1-yl)-cyclohexanol is used as an intermediate in the synthesis of various pharmaceuticals for its ability to be modified to create new molecular entities with desired biological activities. Its structural properties and functional groups contribute to the development of compounds with potential therapeutic effects.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-(3-Benzyloxy-pyrrolidin-1-yl)-cyclohexanol is utilized as a building block for designing and developing new drugs. Its versatility in chemical modifications allows for the exploration of its potential in creating compounds with specific target affinities and biological activities.
Used in Drug Development:
2-(3-Benzyloxy-pyrrolidin-1-yl)-cyclohexanol is employed in drug development processes to enhance the discovery of novel therapeutic agents. Its role as an intermediate aids in the structural optimization of drug candidates, potentially leading to improved pharmacokinetics, pharmacodynamics, and safety profiles.
Used in Chemical Industry:
Beyond its applications in the pharmaceutical sector, 2-(3-Benzyloxy-pyrrolidin-1-yl)-cyclohexanol also finds use in the broader chemical industry. Its unique structure and functional groups make it a valuable component in the synthesis of specialty chemicals and materials with specific applications.

Upstream product

• 177948-70-8 (3R)-N(H)-3-(benzyloxy)pyrrolidine 
• 177947-67-0 (3R)-N-(tert-butyloxycarbonyl)-3-(benzyloxy)pyrrolidine 
• 286-20-4 cyclohexane-1,2-epoxide 
• 100-39-0 benzyl bromide 
• 92645-06-2 (+/-)-trans-2-(N-benzyloxycarbonyl)aminocyclohexanol 
• 931-16-8 (+/-)-trans-2-aminocyclohexanol 
• 143004-34-6 ethyl (R)-3-(benzyloxy)-4-chlorobutanoate 
• 1360870-97-8 (R)-4-(benzyloxy)-1-[(1R,2R)-2-(tert-butyldimethylsiloxy)cyclohexyl]pyrrolidin-2-one 
• 286-20-4 cyclohexene oxide 

Downstream Products

• 795281-92-4 (3R)-3-benzyloxy-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl}pyrrolidine 
• 1370354-77-0 C₂₇H₃₇NO₅ 
• 1370354-64-5 C₂₇H₃₇NO₅ 

Relevant articles and documents

A fang chanfu law compound and its preparation method, pharmaceutical composition and use thereof

The invention relates to a new compound for conversion of auricular fibrillation, as shown in the general formula i in the specification (n in the formula is equal to 0 to 4), or pharmaceutically acceptable salt thereof. The invention also provides a novel compound used as a preventive medicine or therapeutic drug for atrial fibrillation, a preparation method and a pharmaceutical composition containing the compound.

New procedure for the preparation of (1 R,2 R)-2-[(R)-3-(benzyloxy)pyr- rolidin-1-yl]cyclohexanol

A novel route to an intermediate of vernakalant, (1R,2R)-2-[(R)-3- (benzyloxy)pyrrolidin-1-yl]cyclohexanol from ethyl (R)-4-chloro-3- hydroxybutanoate is described. It was found that the key intermediate (R)-4-(benzyloxy)-1-[(1R,2R)-2-(tert-butyldimethylsiloxy)cyclohexyl] pyrrolidin-2-one could be isolated with high dia-stereomeric excess (up to 99% de) from its isomer by column chromatography alone, without further chemical resolution. Georg Thieme Verlag Stuttgart. New York.

PROCESS FOR PREPARATION OF AMINOCYCLOHEXYL ETHERS AND INTERMEDIATE PRODUCTS USED IN THE PROCESS

A process for preparation of a compound of formula (I) or or a pharmaceutically acceptable salt, ester, or prodrug thereof, is disclosed. The process involves hydrogenating, in the presence of a catalyst, a compound of formula (II). The different substituents are as described in the specification. Also disclosed are intermediates and processes for their preparation. Further, the process can provide an alternate route for the synthesis of Vernakalant from starting materials that can be readily available.

SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS

Methods for the preparation of stereoisomerically substantially aminocyclohexyl ether compounds such as trans-(1R,2R)-aminocyclohexyl ether compounds and/or trans-(1S,2S)-aminocyclohexyl ether compounds as well as various intermediates and substrates are disclosed.

PRODUCTION METHOD OF OPTICALLY ACTIVE CYCLOHEXANE ETHER COMPOUNDS

The present invention relates to an industrial synthetic method of an optically active cyclohexane ether compound (IIIa) or a salt thereof, which is useful as a pharmaceutical agent, and an intermediate useful for the production method of the present invention. The production method of the present invention is as shown below: wherein each symbol is as defined in the specification. According to the production method of the present invention, efficient and stable supply of an optically active cyclohexane ether compound (IIIa) in a high yield at a lower cost can be afforded. Therefore, an optically active cyclohexane ether compound (IIIa) extremely useful as a pharmaceutical agent can be provided by an industrially highly advantageous method.